# BeyondSpring Inc. Ordinary Shares (BYSI)

> BeyondSpring Inc. Ordinary Shares (BYSI) trades at $0.6012 (+0.03%) as of 7:30:01 PM EST on Nov 13, 2026, +3.32% over the past month. Market cap is $24.72M, with 41.9 days to cover in short interest.

Canonical: https://massive.com/quote/bysi
Data as of: 2026-11-14T00:30:01.672Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$0.6012** +0.00 (+0.03%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$0.6000** -0.00 (-0.20%)
As of 7:30:01 PM EST on Nov 13, 2026 · After hours

## Stock performance

How BeyondSpring Inc. Ordinary Shares (BYSI) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +0.03% |
| 1W | -3.96% |
| 1M | +3.32% |
| YTD | -63.12% |
| 1Y | -70.67% |
| 52-wk range | $0.42 – $2.44 |

From daily closes through Nov 13, 2026.

## Key statistics

Today's trading snapshot for BYSI: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $0.59 – $0.63 |
| Open | $0.59 |
| Prev close | $0.60 |
| Volume | 33.17K |
| Market cap | $24.72M |
| Shares out | 41.12M |

## Valuation and profitability ratios

Valuation and profitability ratios for BeyondSpring Inc. Ordinary Shares: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | -0.69 |
| P/FCF | — |
| ROE | 18.8% |
| ROA | -45.8% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 13, 2026

## Insider trading

[BeyondSpring Inc. Ordinary Shares (BYSI) insider trading](https://massive.com/quote/bysi/insider-trading.md): open-market Form 4 buys and sells by BeyondSpring Inc. Ordinary Shares insiders over the last 12 months.

## 8-K filings

Material corporate events BeyondSpring Inc. Ordinary Shares has disclosed to the SEC on Form 8-K.

- Nov 13, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 13, 2026, BeyondSpring Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.”
- Oct 6, 2026 · Partnership or collaboration
  “Pursuant to the terms and subject to the conditions set forth in the Purchase and Collaboration Agreement, the Parties established a strategic collaboration with respect to certain development activities involving the conduct and completion of the China portion of DUBLIN-4, a global Phase 3 trial of Plinabulin in combination with docetaxel.”
- Oct 2, 2026 · [Listing deficiency notice](https://massive.com/quote/sec-filings/8-k/delisting-notices.md)
  “On September 29, 2026, BeyondSpring Inc. received a written notification from Nasdaq notifying the Company that, because the Company's market value of listed securities ("MVLS") has fallen below $35 million for the last 30 consecutive business days, the Company no longer complies with the MVLS requirement for continued listing on the Nasdaq Capital Market.”
- Sep 29, 2026 · Divestiture agreement
  “On September 28, 2026, BeyondSpring Inc. entered into a Share Purchase and Collaboration Agreement ... to sell and transfer to the Investor the entire issued share capital in BeyondSpring Ltd., a direct wholly owned subsidiary of the Company.”
- Sep 18, 2026 · [Listing deficiency notice](https://massive.com/quote/sec-filings/8-k/delisting-notices.md)
  “On September 17, 2026, BeyondSpring Inc. (the "Company") received a written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that, because the closing bid price for the Company's ordinary shares ... has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.”

## BYSI short interest

How heavily BYSI is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 41.9 |
| Short interest | 2.28M |
| Avg volume | 54.38K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## BYSI news

The latest news and headlines about BeyondSpring Inc. Ordinary Shares (BYSI).

- [BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path](https://www.globenewswire.com/news-release/2025/12/12/3204554/0/en/BeyondSpring-Announces-ESMO-Asia-Presentation-on-Plinabulin-Docetaxel-Improving-Survival-in-Large-Phase-3-DUBLIN-3-Asian-Subset-for-EGFR-WT-NSCLC-Compared-to-Docetaxel-Strengthenin.html) · GlobeNewswire Inc. · Dec 12, 2025 · positive sentiment
- [SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors](https://www.globenewswire.com/news-release/2025/01/28/3016234/0/en/SEED-Receives-FDA-Rare-Pediatric-Disease-and-Orphan-Drug-Designations-for-Lead-Oncology-Asset-RBM39-Degrader-and-Enters-Strategic-Transactions-with-New-Investors.html) · GlobeNewswire Inc. · Jan 28, 2025 · neutral sentiment
- [BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies](https://www.globenewswire.com/news-release/2025/01/28/3016236/0/en/BeyondSpring-Announces-35-4-Million-Sale-of-a-Portion-of-Equity-Interest-in-SEED-Therapeutics-to-Advance-Lead-Asset-Plinabulin-to-Anti-Cancer-Registrational-Studies.html) · GlobeNewswire Inc. · Jan 28, 2025 · positive sentiment
- [BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior Immune Checkpoint Inhibitors at the 39th SITC Annual Meeting](https://www.globenewswire.com/news-release/2024/11/11/2978241/0/en/BeyondSpring-Presents-Updated-Efficacy-Results-from-a-Phase-2-IIT-Study-of-Triple-IO-Combo-of-Pembrolizumab-plus-Plinabulin-Docetaxel-in-Metastatic-NSCLC-after-Progressing-on-Prior.html) · GlobeNewswire Inc. · Nov 11, 2024 · positive sentiment
- [BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024](https://www.globenewswire.com/news-release/2024/09/16/2946478/0/en/BeyondSpring-Presents-Final-Data-Analysis-of-DUBLIN-3-Phase-3-Study-in-2L-3L-EGFR-Wild-type-NSCLC-at-ESMO-Congress-2024.html) · GlobeNewswire Inc. · Sep 16, 2024 · positive sentiment

## About BeyondSpring Inc. Ordinary Shares

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 44 |
| Listed | Mar 9, 2017 |

[Company website](https://www.beyondspringpharma.com)

## FAQ

### What is the BeyondSpring Inc. Ordinary Shares (BYSI) stock price today?

BeyondSpring Inc. Ordinary Shares (BYSI) is trading at $0.6012 (+0.03% on the day) as of 7:30:01 PM EST on Nov 13, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is BeyondSpring Inc. Ordinary Shares?

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.

### What is the short interest in BYSI?

As of Oct 30, 2026, BYSI has 2.28M shares short and 41.9 days to cover.

### What exchange is BYSI listed on?

BeyondSpring Inc. Ordinary Shares (BYSI) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time BYSI quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=BYSI`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [BeyondSpring Inc. Ordinary Shares (BYSI) insider trading](https://massive.com/quote/bysi/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
